Novo Nordisk: US Senate HELP Committee report on high GLP-1 drug pricing strategies 2025

The $969 List Price: A Senate Investigation

The United States Senate Committee on Health, Education, Labor, and Pensions (HELP) released a majority staff report in 2024 that exposed a pricing chasm for Novo Nordisk’s blockbuster GLP-1 drugs. The investigation, spearheaded by Chair Bernie Sanders, centered on a single, volatile metric: the $969 monthly list price American diabetics pay for Ozempic, a figure that stands in clear contrast to the costs borne by patients in every other wealthy nation.

On September 24, 2024, Novo Nordisk CEO Lars Fruergaard Jørgensen testified before the committee to defend this pricing strategy. The hearing followed the release of data showing that while the U. S. list price for Ozempic hovers near $1, 000, the exact same product is sold for less than $60 in Germany. The committee’s findings suggest that the U. S. market is subsidizing global access, with American patients and insurers paying up to 15 times more than their European counterparts.

Global Price Comparison: The “Tax” on American Patients

The committee’s investigation produced a detailed breakdown of international pricing for semaglutide, the active ingredient in both Ozempic (for type 2 diabetes) and Wegovy (for obesity). The data reveals that the United States is an extreme outlier. While Novo Nordisk cites the complexity of the U. S. rebate system as a driver for high list prices, the base remains the focal point of the Senate’s inquiry.

Table 1: Monthly List Price Comparison for Ozempic and Wegovy (2024)

Country	Ozempic (Type 2 Diabetes)	Wegovy (Obesity)	U. S. Markup Factor
United States	$969. 00	$1, 349. 00	1. 0x (Baseline)
Canada	$155. 00	$265. 00	~6x
Denmark	$122. 00	$186. 00	~8x
United Kingdom	N/A*	$92. 00	~15x
Germany	$59. 00	$137. 00	~16x
France	$71. 00	N/A	~13x

*Note: Prices reflect data presented during the September 2024 Senate HELP Committee hearing. Exchange rates and local negotiations may cause minor fluctuations.

The Manufacturing Cost Reality

A serious component of the Senate’s inquiry involved the actual cost to produce these drugs. The committee research from Yale University, specifically a study by health economist Melissa Barber, which estimated that a monthly supply of Ozempic can be profitably manufactured for less than $5. 00. This figure includes the cost of the active pharmaceutical ingredient (semaglutide), the injection pen, and a profit margin for the manufacturer.

“The problem that we are discussing today is not complicated… In the United States, Novo Nordisk charges us $969 , over 15 times more than they sell it for in Germany. Wegovy, Novo Nordisk’s weight loss drug, is even more expensive… It is a moral problem.”
, Senator Bernie Sanders, Senate HELP Committee Hearing, September 24, 2024

The between a sub-$5 production cost and a nearly $1, 000 list price became the primary line of questioning during Jørgensen’s testimony. The CEO argued that the Yale study failed to account for the billions spent on research and development (R&D) and the capital required to build manufacturing facilities. yet, the committee’s report countered that Novo Nordisk has spent approximately $44 billion on stock buybacks and dividends since 2018, double the amount it allocated to R&D in the same period.

The “Rebate Wall” Defense

During the investigation, Novo Nordisk maintained that the $969 list price is misleading because it does not reflect the “net price” received by the company. Jørgensen testified that Pharmacy Benefit Managers (PBMs), the middlemen negotiating drug plans for insurers, demand high rebates. He claimed that Novo Nordisk pays approximately 74 cents of every dollar back into the system in the form of rebates and fees, leaving the company with a smaller fraction of the list price.

The committee challenged this defense by securing written commitments from the three largest PBMs in the nation: CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth’s Optum Rx. In a strategic move prior to the hearing, Senator Sanders obtained statements from these executives confirming that if Novo Nordisk lowered the list price of Ozempic and Wegovy, the PBMs would not drop the drugs from their formularies. This dismantled the “rebate wall” argument, placing the duty back on the manufacturer to reduce the sticker price.

Economic for the U. S. Healthcare System

The Senate report, released in May 2024 and reiterated during the September hearing, outlined a dire economic forecast if current pricing. The committee modeled the chance impact of widespread GLP-1 adoption on Medicare and the broader healthcare system. The findings indicate that if half of American adults with obesity were prescribed Wegovy at current prices, the annual cost could reach $411 billion. This single expenditure would exceed the total amount Americans spent on all retail prescription drugs in 2022.

The investigation concluded that without a significant reduction in the U. S. list price, the financial load could force a rise in insurance premiums for all Americans, regardless of whether they use the drugs. The committee’s position remains that the U. S. market is being used to generate outsized profits that are not sought in other regulated markets, creating an unsustainable financial trajectory for federal health programs.

Production Cost Analysis: Manufacturing Ozempic for Under Five Dollars

The pricing architecture of Novo Nordisk’s flagship GLP-1 agonists rests on a foundation of extreme markup. A 2024 investigation by researchers from Yale University, King’s College Hospital, and Doctors Without Borders (MSF) revealed that the monthly manufacturing cost for Ozempic (semaglutide) ranges between $0. 89 and $4. 73. This figure includes the cost of active pharmaceutical ingredients (API), formulation, the injection device, and a profit margin with an allowance for tax.

Published in JAMA Network Open, the study exposed a between the physical cost of goods and the commercial list price. While the United States market absorbs a list price of approximately $969 per month, the actual expenditure required to synthesize the drug and package it into a sterile delivery pen is negligible. The that the U. S. list price represents a markup of nearly 20, 000% over the estimated production cost.

Component Cost Breakdown

The Yale researchers, led by Melissa Barber, utilized verified export data and manufacturing cost algorithms to deconstruct the price tag. The analysis dispelled the industry narrative that biologic manufacturing complexity justifies exorbitant pricing. The breakdown of the monthly supply costs includes:

“The profit margin is immense. There should be a conversation in policy about what is a fair price.” , Melissa Barber, Public Health Economist, Yale University.

The primary cost drivers are not the biological agents the logistics of fill-finish and device assembly, both of which remain remarkably low. The active ingredient, semaglutide, accounts for a fraction of the total expense. Specifically, the study estimated the API cost for a month’s supply at approximately $0. 29. The disposable injection pen, frequently as a piece of sophisticated medical engineering, costs roughly $0. 20 to manufacture.

Senate HELP Committee Investigation

During the September 24, 2024, Senate HELP Committee hearing, Chairman Bernie Sanders confronted Novo Nordisk CEO Lars Fruergaard Jørgensen with these figures. The committee’s investigation corroborated the academic findings, noting that generic pharmaceutical executives had confirmed they could profitably sell a bioequivalent version of Ozempic for less than $100 per month, a figure that would still represent a significant profit over the $5 production baseline.

Jørgensen defended the pricing by citing Research and Development (R&D) expenditures, claiming the company spent approximately $4. 2 billion on R&D in 2023. yet, the committee’s report countered this by highlighting that Novo Nordisk spent over $44 billion on stock buybacks and dividends since Ozempic’s 2018 launch, more than double its total R&D spending across all products in the same period.

Global Pricing Disparities

The disconnect between production costs and consumer pricing is unique to the United States. While the manufacturing cost remains constant globally, the retail price fluctuates wildly based on regulatory caps. In Germany, the same product that costs under $5 to make is sold for $59. In the U. S., the absence of negotiation use allows the price to balloon to nearly $1, 000.

Table 1: Monthly Cost vs. List Price Comparison (2024)

Metric	Estimated Cost (USD)
Manufacturing Cost (Yale Estimate)	$0. 89 , $4. 73
Germany List Price	$59. 00
France List Price	$71. 00
Canada List Price	$155. 00
United States List Price	$969. 00

The data confirms that the high U. S. price is not a reflection of manufacturing reality a strategic choice. Even with the “rebate wall” defense, where Novo Nordisk that PBMs absorb 74% of the list price, the net revenue retained by the company in the U. S. still far exceeds the total sales price in European markets. The production cost analysis strips away the complexity of the pharmaceutical supply chain to reveal a simple fact: the drug is cheap to make, expensive to buy.

International Benchmarks: US Patients Pay 15 Times the German Rate

The pricing strategy employed by Novo Nordisk for its semaglutide products, Ozempic and Wegovy, reveals a geographic that penalizes American patients. A 2024 investigation by the U. S. Senate Committee on Health, Education, Labor, and Pensions (HELP) confirmed that the United States list price for Ozempic is $969 per month. In Germany, the exact same product sells for $59. This price differential means American diabetics and taxpayers pay nearly 16 times the amount charged in Europe’s largest economy for the identical life-saving medication.

The German

Germany serves as a primary benchmark in the Senate HELP Committee’s analysis due to its status as a wealthy, developed nation with high safety standards. The $59 German list price for Ozempic covers the manufacturer’s production costs, distribution, and a profit margin. Yet, Novo Nordisk charges United States customers an additional $910 per month for the same four-pen supply. This markup exists even though the drug is manufactured in the same facilities and shipped through similar global logistics networks.

The widens further with Wegovy, the higher-dose version of semaglutide approved for weight loss. In Germany, Wegovy lists for approximately $137 per month. The United States list price stands at $1, 349 per month. American patients engaging in weight management therapy face a financial load ten times heavier than their German counterparts, a fact that Committee Chairman Bernie Sanders highlighted during the September 24, 2024, hearing with Novo Nordisk CEO Lars Fruergaard Jørgensen.

Global Price Comparison

The pricing anomaly is not limited to Germany. Data presented during the Senate investigation shows a consistent pattern where the United States is an outlier among all major economies. While Novo Nordisk maintains profitable operations in Canada, the United Kingdom, and its home country of Denmark, the prices in these regions remain a fraction of the American cost.

Country	Ozempic Monthly Price (USD)	Wegovy Monthly Price (USD)	US Price Multiplier (Ozempic)
United States	$969	$1, 349	1. 0x
Canada	$155	$265	6. 2x
Denmark	$122	$186	7. 9x
United Kingdom	$93 (approx)	$92	10. 4x
France	$71	(Not Listed)	13. 6x
Germany	$59	$137	16. 4x

Source: Senate HELP Committee Majority Staff Report, September 2024. Prices reflect monthly list prices converted to USD.

Senate Testimony and Corporate Defense

During the September 2024 hearing, CEO Lars Fruergaard Jørgensen defended the pricing structure by pointing to the complex system of rebates and Pharmacy Benefit Managers (PBMs) in the United States. Jørgensen argued that the “net price” Novo Nordisk receives is significantly lower than the $969 list price, frequently closer to $600 for Ozempic and $800 for Wegovy after rebates are paid to intermediaries.

The Committee rejected this justification. Chairman Sanders noted that even if the net price were $600, it remains ten times higher than the German list price of $59. The argument that PBMs force high list prices does not explain why the net revenue retained by Novo Nordisk in the US still dwarfs the total revenue per patient in every other developed nation. The Committee’s findings suggest that the US market subsidizes the company’s global operations and shareholder returns, with American patients bearing the entire weight of this financial model.

“Treat the American people the same way that you treat people all over the world. Stop ripping us off.”
, Senator Bernie Sanders, Senate HELP Committee Hearing, September 24, 2024.

Market Arbitrage and Access

The a deliberate market segmentation strategy. In nations with centralized bargaining power, such as the United Kingdom and Canada, Novo Nordisk accepts lower margins to gain market access. In the United States, where Medicare was historically barred from negotiating drug prices and private insurance is fragmented, the company sets prices based on maximum market tolerance. This arbitrage results in a scenario where a single month of treatment in the US costs more than a full year of treatment in Germany.

This pricing structure has tangible consequences for patient access. While German and British health systems can provide these GLP-1 agonists to a broad population of diabetics and obesity patients within their budgets, US insurers and state Medicaid programs frequently restrict coverage due to the prohibitive cost. The Senate report concluded that if Medicare paid the German price for these drugs, the savings would amount to tens of billions of dollars annually, preventing the chance insolvency of the program as demand for GLP-1 therapies accelerates.

Fiscal Impact Projections: A $1 Trillion Threat to US Health Spending

The fiscal trajectory of the United States healthcare system has collided with a mathematical wall: the pricing architecture of Novo Nordisk’s GLP-1 agonists. A majority staff report released by the Senate Health, Education, Labor, and Pensions (HELP) Committee in May 2024 provided a clear actuarial warning: without immediate price intervention, the widespread adoption of Wegovy and Ozempic threatens to push total U. S. prescription drug spending to an $1 trillion annually by 2031.

The $411 Billion Weight Loss Bill

The Senate investigation, led by Chairman Bernie Sanders, modeled the financial shock of GLP-1 uptake scenarios on the American economy. The findings revealed that if 50% of U. S. adults with obesity were prescribed Wegovy or similar weight-loss therapeutics at current net prices, the cumulative cost would reach $411 billion per year. This single expenditure for one class of drugs would exceed the $406 billion Americans spent on all retail prescription drugs combined in 2022. The report underscored that this pricing structure doubles the national drug bill solely to address one condition, creating an unsustainable load on private insurers and public coffers alike.

“There is no rational reason, other than greed, for Novo Nordisk to charge Americans struggling with obesity $1, 349 for Wegovy, when this same exact product can be purchased for just $186 in Denmark.” , Senator Bernie Sanders, May 2024.

Medicare and Medicaid Insolvency Risk

The fiscal threat is most acute for government-sponsored programs. The HELP Committee’s analysis projected that if half of the eligible Medicare and Medicaid populations utilized these medications, the annual cost to taxpayers would swell to $166 billion. To contextualize this figure, the total spending by Medicare and Medicaid for all retail prescription drugs in 2022 was $175 billion. The introduction of mass-market GLP-1 coverage at current price points would double the drug budget for these safety-net programs, forcing a choice between rationing care, raising taxes, or cutting benefits.

Projected Annual GLP-1 Spending vs. 2022 Baselines (50% Uptake Scenario)

Category	2022 Total Drug Spending (Actual)	Projected GLP-1 Cost (Annual)	Fiscal Impact
Total US Retail Market	$406 Billion	$411 Billion	101% of 2022 Total
Medicare & Medicaid	$175 Billion	$166 Billion	95% of 2022 Total
chance Savings (Denmark Pricing)	N/A	-$317 Billion	Massive Deficit Reduction

The $317 Billion Opportunity Cost

The investigation highlighted the between U. S. pricing and international benchmarks as a primary driver of this fiscal emergency. The report calculated that if Novo Nordisk aligned U. S. prices for Wegovy with the $186 monthly rate charged in Denmark, the American healthcare system would save $317 billion annually in the 50% uptake scenario. For Medicare and Medicaid alone, adopting the Danish pricing model would generate $128 billion in annual savings compared to the current U. S. trajectory. These funds, the committee noted, could fully finance the expansion of primary care, dental, and vision benefits for millions of seniors, rather than flowing into the profit margins of a single pharmaceutical entity.

widespread Bankruptcy Warnings

During the September 2024 hearings, expert witnesses and lawmakers warned that the “uncapped” nature of GLP-1 demand, combined with a list price of $1, 349 per month for Wegovy, created a solvency risk for the entire health insurance sector. Blue Cross Blue Shield of Michigan testified to the committee that covering these drugs for all eligible members at current rates would necessitate doubling premiums for all policyholders. Similarly, CVS Health/Caremark described the costs as “overwhelming,” stating there is “simply no way” for clients to fund widespread access without bankrupting plan sponsors. The Senate report concluded that the current pricing strategy is not an problem of affordability a widespread existential threat. With 194 million Americans holding insurance plans that largely exclude these drugs due to cost, the “bankrupting” of the system is already manifesting as a denial of care. The committee’s projections indicate that unless the net price of GLP-1s falls by at least 90%, the U. S. healthcare infrastructure cannot absorb the clinical demand without collapsing under the weight of a trillion-dollar drug bill.

SECTION 5 of 22: Medicare Solvency: The $166 Billion Annual Cost of Obesity Coverage

The $166 Billion Fiscal Cliff

The Senate HELP Committee’s majority staff report, released in May 2024, identifies a specific and imminent threat to the financial stability of the United States’ public health programs. The investigation projects that if 50% of eligible Medicare and Medicaid beneficiaries with obesity were to use Wegovy and similar GLP-1 agonists, the combined annual cost to these programs would reach $166 billion. This single-category expenditure would rival the $175 billion that Medicare and Medicaid spent on all retail prescription drugs combined in 2022.

This projection exposes a mathematical impossibility for the current Medicare funding structure. The report explicitly warns that such an outlay “has the chance to bankrupt Medicare, Medicaid, and our entire health care system.” The analysis relies on current net pricing models, which estimate that even after manufacturer rebates, frequently by Novo Nordisk as a mitigating factor, the U. S. health system pays approximately $809 per month for Wegovy. In clear contrast, the same product is sold for roughly $92 in the United Kingdom and $186 in Denmark.

Utilization and Solvency Impact

The $166 billion figure is not a worst-case outlier a plausible scenario based on disease prevalence. Obesity affects over 40% of the U. S. adult population, creating a vast eligible patient pool that distinguishes GLP-1s from high-cost orphan drugs with limited populations.

“If half of adults with obesity took Wegovy and the other new weight loss drugs, it could cost $411 billion per year , more than what Americans spent on all retail prescription drugs in 2022.” , Senate HELP Committee Majority Staff Report, May 2024

The solvency for the Medicare Hospital Insurance Trust Fund are severe. While Part D (prescription drugs) is funded separately from Part A (hospital insurance), the effects of such massive spending increases would necessitate “historic increases in premiums” for beneficiaries and taxpayers. The committee’s that covering these drugs at current U. S. prices would require a fundamental restructuring of federal health spending, chance displacing funds from other serious care areas.

Current Spending Trajectory (2018, 2024)

Real-world data validates the committee’s concerns about exponential cost growth. Even without broad coverage for weight loss, Medicare Part D spending on GLP-1 drugs for diabetes indications (like Ozempic) has already surged.

Table 5. 1: Medicare Part D Gross Spending on GLP-1 Agonists (2018, 2024)

Year	Gross Spending (Billions)	Primary Indication
2018	$0. 057	Type 2 Diabetes
2022	$5. 7	Type 2 Diabetes
2024	$27. 5	Type 2 Diabetes / CVD

The jump to $27. 5 billion in 2024, driven largely by Ozempic (semaglutide) and Mounjaro (tirzepatide), illustrates the demand. The Senate report that expanding this coverage to the much larger obesity population without a drastic reduction in the $969 (Ozempic) to $1, 349 (Wegovy) list prices would be fiscally catastrophic.

The “Bankrupting” Price Differential

The core of the solvency argument rests on the between U. S. and international prices. The committee calculated that if Novo Nordisk charged Medicare the same price for Wegovy as it charges in Denmark, the cost of covering the entire eligible obesity population would be lower than the cost of covering just 25% of that population at current U. S. rates.

Specifically, the report notes that the U. S. healthcare system could save up to $317 billion per year if U. S. prices matched Danish levels. For Medicare and Medicaid alone, the savings would amount to approximately $128 billion annually. This price gap is not driven by production costs; researchers from Yale University in the report estimate that GLP-1 drugs can be profitably manufactured for less than $5 per month. The gap between a $5 production cost and a ~$809 net price represents the primary threat to Medicare’s long-term fiscal health.

The North Carolina State Health Plan (NCSHP), which covers approximately 740, 000 teachers, state employees, retirees, and their dependents, became the major state government payer to publicly buckle under the financial weight of Novo Nordisk’s pricing strategy. On April 1, 2024, the plan formally terminated coverage for GLP-1 agonists prescribed for weight loss, stripping access from over 20, 000 public servants. This decision, arrived at after a contentious 4-3 vote by the plan’s Board of Trustees, serves as the most prominent case study of the fiscal incompatibility between US drug pricing and public payer solvency.

The $170 Million Fiscal Cliff

State Treasurer Dale Folwell, who oversees the plan, characterized the expenditure on Wegovy and Saxenda as a “financial sinkhole” that threatened the plan’s ability to pay for other medical services. Internal data presented to the Board of Trustees revealed a vertical cost trajectory: spending on GLP-1 medications for weight loss surged from approximately $3 million per month in 2021 to over $14 million per month by late 2023. The projections for 2024 were clear. Plan actuaries estimated that maintaining coverage for weight loss medications would cost the state $170 million in that year alone, with the chance to exceed $1 billion cumulatively over the six years. To sustain this level of spending without cutting benefits elsewhere, the plan would have been forced to increase premiums for *all* members, not just those using the drugs, by $48. 50 per month. This meant asking every teacher and police officer in the state to subsidize the profit margins of a Danish pharmaceutical giant.

“We are not questioning the efficacy of the drugs, we simply can’t afford these medications at the manufacturer’s current price point. It defies logic that Novo Nordisk can sell the exact same product in the Netherlands for $296 per month and in the United States for more than $800 per month.”
, Dale Folwell, North Carolina State Treasurer (2024)

The Rebate “Extortion”

The method of the coverage termination exposed the coercive use exerted by Pharmacy Benefit Managers (PBMs) in the drug supply chain. Initially, the NCSHP Board attempted a compromise: they voted in October 2023 to impose a moratorium on *new* prescriptions starting January 1, 2024, while grandfathering in existing patients to prevent treatment disruption. yet, CVS Caremark, the plan’s PBM, responded by notifying the state that this restriction violated the terms of their rebate agreement. Consequently, the PBM threatened to retract all rebates for the drug class, raising the net price for the 20, 000 existing users by roughly 40%. This maneuver forced the Board’s hand. Faced with the loss of millions in rebates, the Trustees voted in January 2024 to eliminate coverage entirely April 1. Trustee Wayne Fish publicly described the PBM’s tactic as “extortion,” likening the ultimatum to “getting held up at gunpoint in a back alleyway.”

Comparative Market Analysis

The by Treasurer Folwell became a central evidentiary point in the broader Senate HELP Committee investigation. While the NCSHP was being charged over $800 per month (post-rebate) for Wegovy, the same product was available to European public health systems for a fraction of that cost.

Metric	North Carolina State Health Plan	Netherlands Public System
Monthly Cost (Approx.)	$800, $1, 349	$296
Annual Impact (20k users)	~$170 Million	~$71 Million
Premium Hike Required	+$48. 50 / member / month	$0 (Sustainable)

This price differential highlights that the emergency in North Carolina was not driven by utilization volume alone, by a pricing architecture specific to the United States market. Had Novo Nordisk offered the NCSHP the same pricing schedule available in its home country of Denmark or the Netherlands, the $170 million deficit would have been reduced by nearly 60%, likely allowing the state to maintain coverage.

Novo Nordisk’s Response and

Following the vote, Novo Nordisk issued a statement labeling the Board’s decision as “irresponsible” and arguing that it denied patients “medically necessary” treatment. The company urged the Treasurer to reconsider, stating they would “continue to engage” with officials. yet, no substantive offer to lower the list price to European levels was made publicly. The for state employees was immediate. Patients who had successfully managed their weight and related comorbidities like hypertension and pre-diabetes were faced with a choice: pay the full list price of roughly $1, 350 per month out-of-pocket or cease treatment. Clinical that cessation of GLP-1 therapy frequently leads to rapid weight regain, negating the health benefits paid for by the state in previous years. The North Carolina precedent has since reverberated through other state houses. By demonstrating that a large public payer would rather cut coverage than accept the prevailing price point, the NCSHP exposed the upper limit of price elasticity for GLP-1 agonists. The decision signaled to the market that without significant price concessions, the “miracle drug” narrative is insufficient to overcome the mathematical reality of state budget caps.

Capital Allocation: $44 Billion in Buybacks Exceeds R&D Investment

The central defense offered by Novo Nordisk executives for the extreme price of GLP-1 agonists in the United States, that high premiums are necessary to fund complex research and development, collapses under the weight of the company’s own financial disclosures. A forensic review of capital allocation strategies, highlighted by the Senate HELP Committee’s majority staff report, reveals a corporate priority structure that places shareholder returns significantly above scientific innovation. Between 2018 and 2024, the period marking the ascent of Ozempic and Wegovy, Novo Nordisk spent approximately $44 billion on stock buybacks and dividends, a figure more than double the $21 billion allocated to research and development (R&D) in the same timeframe.

The 2-to-1 Ratio: Financialization Over Formulation

The Senate investigation dismantled the “innovation tax” argument by isolating the specific destination of revenue generated from American patients. While U. S. consumers pay list prices up to 15 times higher than their European counterparts, the surplus revenue is not primarily reinvested into the laboratory. Instead, it is funneled into financial method designed to earnings per share (EPS) and distribute cash to investors.

In 2023 alone, Novo Nordisk returned DKK 61. 7 billion (approximately $9 billion) to shareholders through a combination of share repurchases (DKK 29. 9 billion) and dividends (DKK 31. 8 billion). In clear contrast, the company’s total R&D expenditure for the same year was approximately DKK 32. 4 billion. This creates a clear 1. 9-to-1 ratio of shareholder enrichment to research spending, a metric that contradicts the narrative that current pricing levels are an existential requirement for future drug discovery.

Table 7. 1: Novo Nordisk Capital Allocation (2018, 2023 Cumulative)
Source: Senate HELP Committee Majority Staff Report, Novo Nordisk Annual Filings

Category	Allocation (USD Billions)	% of Combined Total	Strategic Purpose
Share Buybacks & Dividends	$44. 0 Billion	67. 7%	Stock Price Support, Investor Yield
Research & Development	$21. 0 Billion	32. 3%	Drug Discovery, Clinical Trials
	+$23. 0 Billion	N/A	Excess Capital Returned to Market

The Mechanics of the Buyback Machine

The mechanics of Novo Nordisk’s share repurchase programs reveal a systematic transfer of wealth from the U. S. healthcare system to global shareholders. By using the outsized profits generated in the unregulated U. S. market, the company executes “Safe Harbour” repurchase programs on the Nasdaq Copenhagen. For the 2024 fiscal year, the company authorized a buyback program of up to DKK 20 billion ($2. 9 billion), explicitly stating the purpose was to “reduce the company’s share capital.”

This financial engineering has a direct impact on the affordability emergency. Senator Bernie Sanders, Chair of the HELP Committee, noted during the September 2024 hearing that if the company simply redirected a portion of its buyback spending toward price stabilization, it could lower U. S. list prices without reducing R&D by a single cent. The $44 billion spent on shareholders since 2018 is sufficient to have fully funded the development of multiple new blockbuster drugs, yet it was instead used to retire stock.

“We are dealing with a moral problem. Novo Nordisk has developed game-changing drugs… they have chosen to use the massive profits from American patients to enrich shareholders rather than expand access.”
, Senator Bernie Sanders, Senate HELP Committee Hearing, September 2024

2025-2026: A Temporary Pause and Rapid Resumption

The rigidity of this capital allocation strategy was briefly tested in 2025. Following the $11. 7 billion acquisition of three manufacturing sites from Catalent, a move necessitated by severe supply absence of Wegovy, Novo Nordisk announced a temporary suspension of its share repurchase program for 2025. This pivot demonstrated that the company possesses the flexibility to reallocate capital when operational imperatives demand it. yet, the pause was short-lived.

By February 2026, even with ongoing scrutiny and unresolved pricing disparities, Novo Nordisk initiated a new share repurchase program of up to DKK 15 billion. This rapid return to buybacks signals to the market that shareholder returns remain the primary directive, even as the company faces political pressure to reduce the $969 list price of Ozempic. The resumption suggests that the “supply chain emergency” was a logistical hurdle, not a catalyst for a permanent shift in capital philosophy toward access or affordability.

R&D Efficiency vs. Marketing Spend

Further eroding the R&D defense is the efficiency of the spending itself. While the company claims high costs are needed for innovation, the Senate report and independent analysts point out that of “operating costs” is directed toward Sales and Distribution (S&D). In fiscal quarters, the combined spend on administration and sales rivals or exceeds the R&D budget. The narrative that every dollar of profit is essential for the breakthrough is mathematically false; for every dollar spent on R&D since 2018, two dollars left the company to pay shareholders.

This allocation profile places Novo Nordisk in line with a broader pharmaceutical industry trend identified by the House Oversight Committee, where 14 major drug companies spent $577 billion on buybacks and dividends between 2016 and 2020, compared to $564 billion on R&D. Novo Nordisk’s ratio, yet, is more aggressive than the industry average, reflecting the unique profitability of the GLP-1 monopoly in the United States.

The “risk premium” defense—a of pharmaceutical pricing strategy—posits that exorbitant U. S. list prices are the necessary engine for future medical breakthroughs. In sworn testimony before the Senate HELP Committee in September 2024, Novo Nordisk CEO Lars Fruergaard Jørgensen articulated this position, warning that aggressive price regulation could sever the capital arteries required to fund the ” breakthrough” and cover the costs of experimental failures. yet, a forensic examination of the company’s financial flows and the broader economic literature deconstructs this narrative, revealing a model prioritized around asset financialization rather than scientific risk-taking.

The Decoupling of Price and Innovation

The central premise of the innovation defense is that revenue from high-margin markets like the United States is directly reinvested into Research and Development (R&D). Senate investigators found a clear between this claim and fiscal reality. Between 2018 and 2024, the period marking the ascent of Ozempic and Wegovy, Novo Nordisk allocated approximately $44 billion to stock buybacks and dividends, more than double the $21 billion earmarked for R&D. This capital allocation strategy suggests that the “risk premium” paid by American patients is not primarily funding the laboratory, rather the shareholder. Economists this represents a shift toward “financialization,” where the primary product of the corporation becomes its own stock price. When excess capital is systematically siphoned out of the company to repurchase shares, the argument that lower prices would starve R&D collapses; the funds are already being diverted away from research.

“The industry is not using these high prices to fund innovation. They are using them to fund stock buybacks and dividends. The argument that we need high prices to have new drugs is simply not supported by the data.”
, Senator Bernie Sanders, Senate HELP Committee Hearing, September 2024

The Sunk Cost Reality

The economic logic of the “risk premium” is further eroded by the nature of pharmaceutical pricing mechanics. A 2021 Congressional Budget Office (CBO) analysis, during the committee’s proceedings, clarified that a drug’s price is determined by what the market bear, not by the R&D costs incurred during its development. These R&D expenditures are “sunk costs”, money already spent that cannot be recovered. For GLP-1 agonists, the foundational risk was taken decades ago. The basic science regarding GLP-1 hormones dates back to the 1980s, with significant early contributions from publicly funded academic research. While Novo Nordisk invested heavily in the specific formulation and delivery method of semaglutide, the current pricing structure in 2025 reflects a “monopoly rent” rather than a reimbursement for ongoing risk. The marginal cost of production, estimated by Yale researchers at under $5 per month, stands in clear contrast to the $969 list price, creating a profit margin that exceeds any reasonable calculation of risk-adjusted return.

The “Innovation Tax” on American Patients

Novo Nordisk’s defense frequently relies on the assertion that the U. S. market subsidizes innovation for the rest of the world. This “free rider” argument suggests that European nations, with their strict price controls, are beneficiaries of American largesse. yet, the Senate report highlights that Novo Nordisk remains highly profitable in markets like Germany ($59/month) and the UK ($92/month). If the company can sustain its operations and R&D pipeline based on European revenue models, the premium charged to U. S. consumers is an “innovation tax” with no distinct return on investment for the payer. The confirms that the U. S. price point is not a requirement for solvency or scientific advancement, a strategic choice enabled by the absence of federal negotiation power prior to the Inflation Reduction Act.

Comparative Financial Flows: 2018, 2024

The following table illustrates the allocation of capital during the serious growth period of Novo Nordisk’s GLP-1 franchise, challenging the correlation between U. S. revenue and R&D intensity.

Financial Category	Amount (Billions USD)	Primary Beneficiary
Stock Buybacks & Dividends	$44. 0	Shareholders
Research & Development	$21. 0	Future Innovation
U. S. List Price (Ozempic)	$969. 00 (per month)	Revenue Generation
German List Price (Ozempic)	$59. 00 (per month)	Market Access

The PBM Scapegoat

During the September 2024 hearing, Jørgensen attempted to deflect responsibility for high list prices onto Pharmacy Benefit Managers (PBMs), arguing that high rebates were necessary to secure formulary placement. He claimed that lowering the list price would paradoxically reduce access because PBMs favor high-priced, high-rebate drugs. This defense was dismantled in real-time. Senator Sanders presented written commitments from the three major PBMs, CVS Caremark, Express Scripts, and Optum Rx, stating they would not drop Ozempic or Wegovy from coverage if Novo Nordisk lowered the list price. This stripped away the “market complexity” defense, leaving the manufacturer’s pricing authority as the sole variable preventing relief for uninsured and underinsured Americans.

Expert Consensus on Financial Extraction

Health economists and policy experts have increasingly categorized the current GLP-1 pricing strategy as extractive. William Lazonick, an economist known for his work on the “financialization” of the pharmaceutical industry, has presented data showing that major drug companies frequently distribute more than 100% of their profits to shareholders when buybacks and dividends are combined, borrowing money to finance the difference., the “risk premium” is not a reserve fund for future science; it is a method for wealth transfer. The Senate HELP Committee’s findings suggest that the innovation defense is a retrospective justification for pricing power, rather than a prospective budget for medical progress. The continued solvency and R&D output of the company in price-regulated markets proves that the “risk” has long been mitigated, while the “premium” endures.

The September 2024 Showdown: A Public Refusal

On September 24, 2024, the Senate Health, Education, Labor, and Pensions (HELP) Committee convened a highly anticipated hearing titled “Why Is Novo Nordisk Charging Americans with Diabetes and Obesity Outrageously High Prices for Ozempic and Wegovy?” The session marked a rare direct confrontation between U. S. lawmakers and the leadership of the Danish pharmaceutical giant. At the center of the proceedings was Novo Nordisk CEO Lars Fruergaard Jørgensen, who faced aggressive questioning from Chairman Bernie Sanders regarding the between the $969 U. S. list price for Ozempic and the roughly $59 price tag for the same product in Germany.

The hearing was designed to the pharmaceutical industry’s primary defense for high list prices: the rebate trap. For years, manufacturers have argued that they cannot lower list prices because Pharmacy Benefit Managers (PBMs) would punish them by removing their drugs from formularies, preferring instead to retain the high rebates associated with inflated sticker prices. Jørgensen relied heavily on this defense during his testimony, stating that “we pay 75 cents of every dollar of medicine we sell back into this complex system in rebates, discounts, and fees.”

The PBM Gambit

In a strategic maneuver intended to corner the CEO, Senator Sanders revealed that he had obtained written commitments from the nation’s three largest PBMs, CVS Caremark, Express Scripts, and Optum Rx. These three entities control approximately 80% of the prescription drug market in the United States. The letters, entered into the congressional record, explicitly stated that the PBMs would not limit coverage or remove Ozempic and Wegovy from their formularies if Novo Nordisk substantially lowered the list price.

Sanders presented this evidence directly to Jørgensen, removing the CEO’s primary shield. “I am delighted to announce today that I have received commitments in writing from all of the major PBMs that if Novo Nordisk substantially reduced the list price for Ozempic and Wegovy, they would not limit coverage,” Sanders stated. He then posed a direct question: with the threat of formulary exclusion removed, would Novo Nordisk commit to lowering the list price for American patients?

Jørgensen’s Refusal to Commit

even with the public assurances from the PBMs, Jørgensen refused to commit to a price reduction. Instead, he expressed skepticism regarding the PBMs’ pledge, citing historical precedent over the written pledges. He pointed to the company’s experience with Levemir, an insulin product. According to Jørgensen, when Novo Nordisk reduced the list price of Levemir by 65%, insurance coverage for the drug plummeted from 90% to 36%, forcing the company to eventually discontinue the product.

“I have to understand what this entails,” Jørgensen testified, avoiding a “yes” or “no” answer. “The experience we have is one of losing access when we lower prices.”

This refusal highlighted a serious impasse. While the CEO expressed a willingness to “collaborate” and “look into” the PBM offers, he maintained that the widespread incentives of the U. S. market made a unilateral price cut too risky for the company’s bottom line and market share. The testimony confirmed that Novo Nordisk prioritizes the rebate-driven business model over direct list price reductions, even when presented with a chance off-ramp by the intermediaries themselves.

The “75 Cents” Defense

Throughout the hearing, Jørgensen attempted to shift the focus from the list price to the “net price”, the amount the company actually receives after rebates. He argued that the $969 list price is a fiction for most payers, and that the company’s retained revenue is significantly lower. yet, this defense failed to address the reality for the uninsured, those with high-deductible plans, and the co-insurance calculations that are frequently based on the inflated list price rather than the net price.

“Stop ripping us off. Treat the American people the same way that you treat people all over the world.”
, Senator Bernie Sanders, addressing CEO Lars Fruergaard Jørgensen, September 24, 2024.

The hearing concluded without any concessions from Novo Nordisk. Jørgensen’s testimony made it clear that without legislative intervention or a complete restructuring of the PBM rebate system, the company intends to maintain its high-list, high-rebate pricing strategy for its GLP-1 blockbusters. The CEO’s stance placed the load of high prices back onto the structural dysfunction of the U. S. healthcare system, absolving the manufacturer of direct responsibility for the sticker price.

Comparison of Claims: Senate HELP Committee vs. Novo Nordisk CEO

problem	Senate HELP Committee Position	Novo Nordisk CEO Defense
List Price	$969 (Ozempic) is excessive compared to $59 in Germany.	List price is a “starting point” for negotiations; few pay it.
PBM Obstacles	PBMs committed in writing to support price cuts.	PBMs dropped coverage for Levemir after price cuts; skepticism of pledges.
Revenue Retained	Company profits are disproportionately high in the U. S.	Company retains only ~25 cents of every dollar after rebates/fees.
Solution	Immediate reduction of list price to match international peers.	widespread reform of the PBM/rebate model required.

SECTION 10 of 22: The PBM Rebate Wall: Insurers Confirm Willingness to Accept Lower Prices

The “Rebate Wall” Defense

During the September 24, 2024, Senate HELP Committee hearing, Novo Nordisk CEO Lars Fruergaard Jørgensen mounted a specific defense for the $969 list price of Ozempic: the “rebate wall.” Jørgensen testified that the United States healthcare system forces pharmaceutical companies to set artificially high list prices to accommodate the financial demands of Pharmacy Benefit Managers (PBMs). According to Jørgensen, these intermediaries, who negotiate drug benefits for insurers and employers, require large rebates to place drugs on favorable formulary tiers.

Jørgensen presented internal metrics stating that Novo Nordisk retains only approximately 26 cents of every dollar spent on its GLP-1 medicines in the U. S., with the remaining 74 cents absorbed by the “complex supply chain” of PBMs, insurers, and fees. He argued that unilaterally lowering the list price would be commercially suicidal, citing the company’s experience with its insulin product, Levemir. Jørgensen claimed that after Novo Nordisk reduced the list price of Levemir by 65% in 2023, PBMs responded by dropping the drug from formularies, causing patient access to plummet from 90% to roughly 35%.

The Senate’s Strategic Rebuttal

Committee Chair Bernie Sanders dismantled this defense by revealing a coordinated preemptive investigation. Prior to the hearing, the Committee secured written commitments from the three largest PBMs in the United States, CVS Caremark (CVS Health), Express Scripts (The Cigna Group), and Optum Rx (UnitedHealth Group), which shared control 80% of the prescription drug market.

Sanders entered these letters into the congressional record, directly contradicting the pharmaceutical giant’s claim that lower prices would result in formulary exclusion. The PBMs explicitly stated that they would maintain or expand coverage for Ozempic and Wegovy if Novo Nordisk lowered the list price.

CVS Caremark Statement to Senate HELP Committee:
“The simple answer is no. In fact, we can point to recent history as a proof point. When Novo Nordisk drastically reduced the price of their insulin, Novolog, in 2023, it did not result in a less favorable formulary placement with Caremark.”

Express Scripts (Cigna) Statement to Senate HELP Committee:
“No, if Novo Nordisk lowered their list price for Ozempic and Wegovy tomorrow to a price that was the same or lower than current net cost, that change by itself would not result in less favorable formulary placement.”

Optum Rx (UnitedHealth) Statement to Senate HELP Committee:
“Assuming the net price remains the same or lower, lowering a medicine’s list price would not lead to less favorable formulary placement by Optum Rx , particularly for high-demand drugs like Ozempic and Wegovy.”

The Mathematical Reality of “Net Price”

While the “rebate wall” explains the method of list pricing, investigative analysis of the financial flows reveals that it does not account for the absolute cost. Even accepting Jørgensen’s testimony that Novo Nordisk retains only 26% of the list price, the revenue generated per U. S. patient remains significantly higher than the full list price in peer nations.

If Novo Nordisk retains 26% of the $969 U. S. list price for Ozempic, the company nets approximately $251. 94 per monthly prescription. This “net” amount, after all PBM rebates and fees are stripped away, is still more than four times higher than the full $59 list price in Germany. This data point suggests that while PBM rebates the gross price, they do not explain why the net revenue extracted from the U. S. market is multiples higher than the gross revenue accepted in Europe.

Comparative Revenue Analysis

Metric	United States (Ozempic)	Germany (Ozempic)	Factor
List Price (Monthly)	$969. 00	$59. 00	16. 4x
Novo Nordisk Retained Share	~26% (Claimed)	100% (Est.)	N/A
Net Revenue to Novo	$251. 94	$59. 00	4. 3x

The hearing concluded with a standoff. Jørgensen expressed skepticism regarding the PBMs’ public pledges, stating he would be “happy to sit down” with them remained wary of a repeat of the Levemir scenario. yet, the written evidence provided by the insurers removed the primary external justification for the high list prices, isolating Novo Nordisk’s pricing strategy as a deliberate corporate choice rather than a widespread inevitability.

SECTION 11 of 22: Net Price Reality: Hidden Discounts Fail to Reach Uninsured Patients

The Rebate Wall: Subsidizing Insurers at Patient Expense

While Novo Nordisk executives emphasize that the “net price” of Ozempic and Wegovy, the amount the company actually retains after rebates, is significantly lower than the public list price, this distinction offers no relief to the uninsured or underinsured. Senate HELP Committee findings from 2024 and 2025 reveal a structural inequity where the highest prices are paid by the most patients. The list price for Ozempic ($969) and Wegovy ($1, 349) serves as the starting point for the uninsured at the pharmacy counter, while Pharmacy Benefit Managers (PBMs) and insurers negotiate deep discounts that remain invisible to the consumer.

In sworn testimony, Novo Nordisk CEO Lars Jørgensen stated that the company pays approximately 75 cents of every dollar in rebates and fees to intermediaries, placing the net revenue for Ozempic closer to $600 per month. yet, this rebate system creates a “reverse subsidy”. Uninsured patients, who absence the bargaining power of a PBM, are frequently charged the full Wholesale Acquisition Cost (WAC). Consequently, a cash-paying patient in the United States may pay nearly double what a commercial insurer pays for the same unit of semaglutide, subsidizing the rebates that flow back to corporate payers.

The “Cash Pay” Mirage: Temporary Fixes vs. Structural blocks

In response to intensifying legislative pressure, Novo Nordisk has rolled out various “savings card” and “cash pay” initiatives, yet these programs are with exclusions and expiration dates that limit their utility as a safety net. As of February 2026, the company promotes a direct-to-patient cash price for Wegovy and Ozempic, frequently marketed at $199 for the two months. yet, a closer examination of the terms reveals a steep cliff:

2026 “Cash Pay” Program Limitations for Semaglutide

Program Feature	Ozempic (Diabetes)	Wegovy (Obesity)
Introductory Price	$199/month (Months 1-2)	$199/month (Months 1-2)
Standard Cash Price	$349, $499/month (Dose dependent)	$349/month (Maintenance)
Medicare Eligibility	EXCLUDED	EXCLUDED
Uninsured Income Cap	<200% Federal Poverty Level	<200% Federal Poverty Level
German Benchmark	$59/month	$137/month

Even with these “discounted” cash rates, American patients pay between 300% and 500% more than the standard retail price in Germany or the United Kingdom. also, the $349 maintenance price remains prohibitively expensive for the median uninsured household. The program’s design also strictly excludes government beneficiaries; a senior citizen on Medicare Part D who falls into the “donut hole” coverage gap cannot access these cash-pay cards, leaving them exposed to the full list price or high coinsurance rates.

2026 Policy Shift: The Medicare Exclusion

The for populations widened significantly in January 2026, when Novo Nordisk altered the eligibility criteria for its Patient Assistance Program (PAP). Citing that “98% of Medicare beneficiaries have access” to Ozempic, the company eliminated PAP eligibility for Medicare Part D enrollees. This policy shift removed the safety net for seniors who, even with having “access” on paper, face unaffordable out-of-pocket costs due to deductibles and co-pays.

“The removal of Medicare beneficiaries from the Patient Assistance Program in 2026 forces fixed-income seniors to choose between rent and a $300 co-pay, while the manufacturer claims ‘access’ is solved.”
, Senate HELP Committee Hearing Testimony, September 2024

For the uninsured, the PAP income threshold remains set at 200% of the Federal Poverty Level (approximately $30, 000 for a single individual). This leaves a vast “middle class” of uninsured or underinsured workers, those earning between $30, 000 and $70, 000, in a financial no-man’s-land. They earn too much to qualify for free medication too little to afford the $349 monthly “discount” price, let alone the $969 list price.

Future Price Cuts: Too Little, Too Late?

On February 24, 2026, facing the threat of subpoenaed internal documents and public outcry, Novo Nordisk announced a reduction in the US list price for Ozempic and Wegovy to $675, January 1, 2027. While this move ostensibly narrows the gap between list and net prices, it does not take effect until the following year. For the entirety of 2026, the pricing architecture remains unchanged. also, a $675 list price is still more than ten times the cost of the drug in peer nations, confirming that even the “corrected” price continue to penalize the US healthcare system and its uninsured patients.

Patent Evergreening: FTC Scrutiny of Device Modifications

The regulatory siege on Novo Nordisk’s pricing architecture intensified in April 2024 when the Federal Trade Commission (FTC) formally challenged the company’s use of the FDA Orange Book to block generic competition. The FTC’s investigation focused on “junk patent” listings, specifically, the practice of listing device-related patents, such as injection pen method, as drug patents to trigger automatic 30-month stays on generic approvals. This strategy, known as “evergreening,” extends the monopoly on Ozempic and Wegovy beyond the expiration of the active ingredient, semaglutide.

The “Junk Patent” Crackdown

On April 30, 2024, the FTC issued warning letters to ten pharmaceutical manufacturers, identifying over 300 patents across 20 brand-name products as improperly listed. Novo Nordisk was a primary target. The Commission specifically flagged patents associated with Ozempic (semaglutide), Saxenda (liraglutide), and Victoza (liraglutide). The agency argued that these patents, which cover mechanical components like dosage dials and needle shields, do not meet the statutory requirements for listing in the Orange Book because they do not claim the active drug ingredient or its method of use.

By listing these device patents, Novo Nordisk use the Hatch-Waxman Act to freeze FDA approval of generic competitors. When a generic manufacturer files an Abbreviated New Drug Application (ANDA), they must certify against listed patents. If Novo Nordisk sues for infringement on these device patents, the FDA is legally barred from approving the generic for up to 30 months, regardless of the patent’s validity. This regulatory bottleneck preserves the $969 monthly list price of Ozempic against competitors that could be profitably manufactured for under $5.

Senate HELP Committee Investigation

The Senate Committee on Health, Education, Labor, and Pensions (HELP), led by Chair Bernie Sanders, directly coordinated its inquiry with the FTC’s findings. In a letter dated April 24, 2024, the Committee demanded Novo Nordisk justify the inclusion of specific device patents in the Orange Book. The investigation highlighted that these patents add no clinical value to the drug itself serve as formidable blocks to market entry.

The Committee specifically three patents that exemplify the “thicket” strategy used to insulate the semaglutide franchise from competition:

Table 12. 1: Novo Nordisk Device Patents Under Senate and FTC Scrutiny

Patent Number	Description of Invention	Regulatory Function	Status (2025)
US 9, 108, 002	Automatic injection device with top release method	Blocks generic pens with similar release triggers	Challenged by FTC
US 9, 132, 239	Dial-down method for wind-up pen	Prevents generics from using standard dosage dials	Challenged by FTC
US RE46363	Reissue: Dial-down method for wind-up pen	Extends exclusivity on the mechanical dosing interface	Subject to Senate Inquiry

Novo Nordisk’s Refusal to Delist

even with the regulatory pressure, Novo Nordisk refused to remove the disputed patents from the Orange Book. In June 2024, the company formally responded to the FTC, asserting that its listings were appropriate and compliant with FDA regulations. This refusal forced the FTC to escalate its enforcement actions. By May 2025, the FTC issued a third round of warning letters, expanding its dispute to include over 200 additional patents across the industry, further entrenching the conflict between federal antitrust enforcers and the Danish pharmaceutical giant.

“By filing bogus patent listings, pharma companies block competition and the cost of prescription drugs, forcing Americans to pay sky-high prices for medicines they rely on.” , Lina M. Khan, FTC Chair, April 30, 2024

The 2026 Patent Cliff and Global

The strategic importance of these device patents is magnified by the looming expiration of the primary semaglutide molecule patent. While the active ingredient patent is set to expire in key markets like China and Brazil in 2026, the US patent thicket, by these device modifications, aims to extend exclusivity domestically until at least 2032. This gap creates a bifurcated global market where US patients and insurers continue to pay premium monopoly prices while international markets prepare for the entry of low-cost biosimilars and generics.

The persistence of these device patents prevents “skinny labeling,” a pathway where generic manufacturers seek approval for unpatented uses of a drug. Because the pen device is integral to the administration of the drug for all indications, the device patents block all generic versions of Ozempic and Wegovy, regardless of the specific medical indication being treated.

SECTION 13 of 22: Generic Suppression: Legal Action Against Pharmacies

The Litigation Barrage: 132 Lawsuits to Protect the Monopoly

While the Senate HELP Committee investigated the $969 list price of Ozempic, Novo Nordisk executed a parallel strategy to the only market force offering a lower price: the pharmacy industry. Between June 2023 and August 2025, the pharmaceutical giant filed at least 132 lawsuits across 40 states targeting medical spas, wellness clinics, and pharmacies. These legal actions, combined with thousands of cease-and-desist letters, formed a systematic campaign to suppress lower-cost alternatives that had emerged during the FDA- drug absence.

The economic threat posed by compounders was existential to Novo Nordisk’s pricing architecture. While the brand-name Wegovy listed for over $1, 300 per month, pharmacies offered semaglutide formulations for approximately $200 to $400. This 70% to 85% price differential exposed the extreme markup of the branded product and provided a lifeline for patients whose insurance denied coverage. In response, Novo Nordisk deployed a legal strategy centered on trademark infringement and “false advertising,” arguing that these compounded versions were unauthorized, unsafe, and confusingly similar to their FDA-approved products.

The FDA absence Loophole and the February 2025 Pivot

The legal foundation for the industry rested on Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which permits pharmacies to create alternative versions of a drug when it appears on the FDA’s absence list. For nearly three years, the scarcity of Ozempic and Wegovy allowed compounders to legally fill the supply gap. Novo Nordisk aggressively lobbied to close this window.

On February 21, 2025, the FDA officially declared the semaglutide absence “resolved,” a determination based largely on supply data provided by Novo Nordisk itself. This regulatory milestone triggered an immediate legal escalation. With the absence designation removed, the “essentially a copy” provision of the FD&C Act reactivated, making it illegal for compounders to mass-produce semaglutide.

The impact was swift. By April 2025, federal courts in Texas denied motions from the Outsourcing Facilities Association to halt the FDA’s decision, ending the grace period for 503A pharmacies immediately and setting a May 22, 2025, deadline for 503B outsourcing facilities to cease production. This regulatory maneuver wiped out the primary source of affordable semaglutide for hundreds of thousands of U. S. patients, forcing them back into the full-price market.

Weaponizing Safety: The “Salt Form” Narrative

Beyond regulatory technicalities, Novo Nordisk utilized a narrative of patient safety to justify its litigation. In court filings and public statements throughout 2024 and 2025, the company emphasized that compounders used semaglutide sodium or semaglutide acetate, salt forms of the active ingredient, rather than the FDA-approved semaglutide base.

Novo Nordisk commissioned testing of compounded products from two Florida pharmacies, releasing results in June 2024 that alleged “high levels of unknown impurities” (up to 33% in one sample) and lower-than-labeled potency. These findings were weaponized in court to secure permanent injunctions. For instance, in April 2025, a federal court in Tennessee permanently barred Midtown Express from selling compounded semaglutide after Novo proved the product contained no active semaglutide at all. While such cases highlighted genuine bad actors, industry advocates argued that Novo used these extreme examples to paint the entire regulated sector as dangerous, conflating legitimate 503B facilities with unregulated medical spas.

Economic: The Price of Suppression

The elimination of compounded semaglutide removed the only price anchor in the U. S. market. The table illustrates the cost that Novo Nordisk’s legal team fought to preserve.

Table 13. 1: Cost Comparison of Semaglutide Sources (2024-2025)

Product Source	Monthly Cost (Est.)	FDA Approved?	Availability Status (Post-Feb 2025)
Novo Nordisk (Ozempic)	$969	Yes	Available
Novo Nordisk (Wegovy)	$1, 349	Yes	Available
503B Pharmacy	$200, $450	No	Restricted / Illegal
Telehealth Subscription (Compounded)	$299	No	Litigation Target

Targeting Telehealth and “Secret Shoppers”

To execute this crackdown, Novo Nordisk employed private investigators and “secret shopper” programs. In 2024, the company admitted to testing products purchased from dozens of clinics to build its evidence base. By mid-2025, the focus shifted from small clinics to major telehealth platforms.

Lawsuits filed in August 2025 targeted telehealth companies that attempted to circumvent the absence resolution by claiming their products were “individualized” for specific patients, a narrow exception in law. Novo argued that these companies were engaged in “mass ” under the guise of personalization. The company secured default judgments and settlements requiring clinics to publicly retract claims that their products were “generic Ozempic.”

“The removal of semaglutide from the FDA absence list was not just a supply chain milestone; it was a foreclosure notice for the affordable market. By successfully arguing that supply met demand, Novo Nordisk legally eradicated its only price competition.”

The Senate HELP Committee’s investigation noted that while patent protection is a legal right, the aggressive litigation against compounders during a period of high demand served to insulate the $969 price point from market realities. By the end of 2025, with the loophole largely closed, American patients were left with a binary choice: pay the world’s highest prices for the brand-name drug or go without treatment.

The “Pay Twice” model: Public Risk, Private Profit

The Senate HELP Committee’s investigation into Novo Nordisk’s pricing strategies has crystallized a central grievance: the American taxpayer is paying for semaglutide twice., through billions in federal funding that underwrote the foundational discovery of the GLP-1 hormone, and second, through the highest list prices in the world for the resulting commercial products, Ozempic and Wegovy. The committee’s majority staff report, released in 2024, challenges the pharmaceutical industry’s standard defense, that high prices are necessary to recoup high-risk research and development costs, by documenting the substantial de-risking provided by the National Institutes of Health (NIH).

According to data provided to the committee and independent investigators, the scientific bedrock of the GLP-1 class was laid not in corporate laboratories in Denmark, in federally funded academic institutions in the United States. Senator Bernie Sanders, Chair of the HELP Committee, has repeatedly characterized this as “socialized risk and privatized profit,” noting that while Novo Nordisk refined the delivery method, the biological engine of the drug was ignited by U. S. tax dollars.

The $6. 2 Billion Taxpayer Investment

A serious component of the committee’s evidence comes from an analysis by researchers at Bentley University’s Center for Integration of Science and Industry. The data reveals that the U. S. federal government invested approximately $6. 2 billion between 1980 and 2024 in the discovery and development of glucagon-like peptide-1 (GLP-1) molecules and their application to diabetes and obesity.

This funding was not peripheral; it targeted the “basic science” phase of development, the high-risk period where the biological method of disease are identified. Pharmaceutical companies avoid this stage due to its high failure rate, preferring to acquire or license compounds once the biological have been validated by public funding. The Bentley analysis indicates that the NIH contributed to the research associated with every single one of the 210 new drugs approved by the FDA between 2010 and 2016, with the GLP-1 class representing a particularly heavy public investment due to the complexity of the hormone’s biology.

Foundational Discovery: The Habener Connection

The committee’s report highlights the specific contributions of Dr. Joel Habener, a researcher at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. In the 1980s, supported by continuous NIH grants, Dr. Habener’s laboratory was among the to identify and clone the GLP-1 hormone. His work demonstrated that GLP-1 stimulates insulin production, a discovery that forms the method of action for all subsequent drugs in the class, including Ozempic and Wegovy.

In 2024, Dr. Habener received the Lasker Award, frequently a precursor to the Nobel Prize, for this discovery. The Senate investigation show that this award-winning research was not funded by Novo Nordisk, by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a branch of the NIH. The committee that without this publicly funded “map” of the human endocrine system, Novo Nordisk’s product development would have been impossible.

The “Fair Pricing” Void

even with this clear lineage of public funding, the U. S. government absence a direct method to enforce pricing conditions on the resulting products. The report details a serious policy shift that occurred in 1995, when the NIH revoked its “fair pricing” clause. Previously, this clause required that products developed with federal funds be made available to the public at a reasonable price.

Since the revocation, the NIH has reportedly not exercised its “march-in rights” under the Bayh-Dole Act of 1980, which theoretically allows the government to license a patent to other manufacturers if the original patent holder fails to make the invention available to the public on reasonable terms. The HELP Committee has scrutinized this passivity, with Senator Sanders urging the Department of Health and Human Services (HHS) to reinstate fair pricing requirements for all future NIH grants and to consider using existing statutory authority to address the pricing of GLP-1s.

Return on Investment Analysis

The between the public’s input and the public’s cost is clear when viewed through the lens of return on investment (ROI). While the federal government spent $6. 2 billion over four decades to the creation of the GLP-1 class, Novo Nordisk generated nearly $50 billion in revenue from Ozempic and Wegovy in the U. S. market alone within just a few years of their launch.

Investment Source	Contribution Type	Estimated Amount	Financial Return
U. S. Taxpayers (NIH)	Basic Science & Discovery (1980-2024)	$6. 2 Billion	Negative (High procurement costs for Medicare/Medicaid)
Novo Nordisk	Product Formulation & Clinical Trials	Undisclosed (Est. <$10B for class)	$50 Billion+ (Revenue to date)

Legal Remedies: 28 U. S. C. § 1498

of the refusal by Novo Nordisk to voluntarily lower prices to match European levels, the committee has explored the use of 28 U. S. C. § 1498. This statute allows the federal government to use or manufacture any patented invention without the patent holder’s permission, provided it pays “reasonable and entire compensation” to the owner.

Legal experts testifying before the committee have argued that § 1498 was designed precisely for this scenario: to prevent patent monopolies from holding the government hostage. By invoking this code, the government could theoretically contract with generic manufacturers to produce semaglutide for federal programs like Medicare and the VA, bypassing Novo Nordisk’s monopoly pricing while still paying the company a royalty. The committee’s report suggests that the mere threat of this action could be sufficient to bring Novo Nordisk to the negotiating table, similar to how the government successfully negotiated lower prices for Cipro during the 2001 anthrax scare.

SECTION 15 of 22: Lobbying Operations: Record Spending to Protect US Pricing Models

The Washington Blitz: A Financial Escalation

As regulatory scrutiny intensified between 2023 and 2025, Novo Nordisk executed a historic expansion of its federal lobbying operations. Senate disclosures reveal a strategic pivot from standard corporate advocacy to a emergency-management footing, designed to protect the company’s U. S. pricing architecture against the Inflation Reduction Act (IRA) and Senate investigations.

In the quarter of 2025 alone, Novo Nordisk spent $2. 8 million on federal lobbying, a 38. 9% increase from the previous quarter. This surge coincided with the Senate HELP Committee’s preparation for its September 2024 hearing on GLP-1 pricing. The company’s lobbying corps expanded from 28 registered lobbyists in 2019 to 50 lobbyists by the end of 2022, a force that included former congressional staffers and legislative directors.

The financial trajectory of this influence campaign demonstrates a clear correlation with the rising political threat level. By late 2025, quarterly spending remained elevated at $2. 12 million in Q4, cementing a new baseline for the company’s Washington expenditures.

Table 15. 1: Novo Nordisk Federal Lobbying Expenditure Surge (Selected Quarters)

Period	Expenditure	Key Context
Q1 2023	$1. 45 Million (Est.)	Initial surge following widespread Wegovy absence and media attention.
Q4 2024	$1. 24 Million	Preparation for incoming Senate HELP Committee scrutiny.
Q1 2025	$2. 80 Million	Record “blitz” targeting Medicare coverage expansion and IRA implementation.
Q4 2025	$2. 12 Million	Sustained pressure during finalization of Medicare price negotiation lists.

Legislative: The “Treat and Reduce” Strategy

Novo Nordisk’s lobbying apparatus concentrated its firepower on specific legislative vehicles designed to unlock government coffers for its weight-loss drugs. The primary target was the Treat and Reduce Obesity Act (TROA) (H. R. 4818 / S. 2407 in the 2023-2024 session; re-introduced as H. R. 4231 / S. 1973 in 2025). The bill sought to amend the Medicare Social Security Act to allow Part D coverage for weight-loss medications, a change that would transfer the high cost of Wegovy from private patients to the federal taxpayer.

Simultaneously, the company lobbied heavily on the implementation of the Inflation Reduction Act (IRA). After the Third Circuit Court of Appeals rejected Novo Nordisk’s legal challenge to the IRA’s drug price negotiation provisions in 2025, the company’s lobbyists shifted focus to influencing the Centers for Medicare & Medicaid Services (CMS) on the technical implementation of the law. This included efforts to shape how “negotiation-eligible” drugs were defined, specifically arguing against the bundling of different insulin products (Fiasp and NovoLog) as a single source drug.

The “Echo Chamber” Strategy: Funding Patient Advocacy

A serious component of Novo Nordisk’s influence strategy involved the funding of third-party patient advocacy groups to create a “grassroots” demand for coverage. This “echo chamber” effect allowed the company to amplify its commercial goals through the voices of patients and medical associations.

In June 2024, the American Diabetes Association (ADA) launched its “Obesity Association” division with a “multi-year commitment” of funding from Novo Nordisk. While the stated mission was to “challenge stigmas” and educate professionals, the partnership aligned the nation’s leading diabetes organization with Novo’s commercial imperative to classify obesity as a chronic disease requiring lifelong pharmaceutical intervention.

Similarly, the company provided financial support to the Obesity Action Coalition (OAC), a patient group that actively lobbies lawmakers to pass the Treat and Reduce Obesity Act. By subsidizing these organizations, Novo Nordisk generated a steady stream of patient testimonials and “access to care” narratives that mirrored its own corporate talking points, insulating the company from direct accusations of profit-seeking.

The “Middleman” Defense and Strategic Concessions

During the September 2024 Senate HELP Committee hearing, Novo Nordisk CEO Lars Fruergaard Jørgensen deployed a “middleman” defense strategy. He argued that the $969 list price for Ozempic was misleading because Pharmacy Benefit Managers (PBMs) absorbed a vast majority of the revenue through rebates and fees.

“Whatever the cost is, Novo Nordisk keeps 26% of it, and the PBMs extract 74%, so really, the PBMs are making the bank here.”
, Senator Roger Marshall (R-KS), summarizing Novo Nordisk’s position during the 2024 hearing.

This narrative attempted to shift legislative anger toward PBMs, aligning with the PBM Reform Act which Novo Nordisk also lobbied for. yet, this defense faced skepticism when contrasted with the company’s net profits and the significantly lower prices offered in European markets where PBMs do not exist.

Facing the dual threat of the IRA’s Medicare price negotiations and sustained public outrage, Novo Nordisk eventually signaled a strategic retreat. In February 2026, the company announced it would lower the U. S. list prices of Wegovy and Ozempic to roughly $675, January 1, 2027. This move, while presented as a measure to improve affordability, was calculated to align the list price with the inevitable “Maximum Fair Price” that would be established by Medicare negotiations, so preempting further regulatory enforcement while maintaining a price point still significantly higher than international benchmarks.

SECTION 16 of 22: Physician Payments: Tracking Consulting Fees and Travel Perks

The “Education” Loophole: A $11 Million Meal Tab

While the Senate HELP Committee focused on the sticker price of Ozempic and Wegovy, a parallel method has quietly cemented Novo Nordisk’s market dominance: a massive, granular campaign of physician subsidization. Federal Open Payments data reveals that in 2022 alone, Novo Nordisk spent $11 million specifically on meals and travel to promote its GLP-1 agonists. This figure does not represent of high-level conferences a saturation strategy; the company purchased over 457, 000 individual meals for prescribers in a single year.

The of this operation transforms the concept of “medical education” into a routine financial touchpoint. Analysis of 2022 that nearly 12, 000 US prescribers had their food paid for by Novo Nordisk more than a dozen times. For physicians, the frequency was daily; one high-volume prescriber recorded 193 separate meals funded by the company in a single year. These interactions, frequently categorized as “informational presentations,” allow sales representatives to maintain constant physical access to the clinicians controlling the prescription pad.

The “Key Opinion Leader” Payroll

Beyond the daily catering of local clinics, Novo Nordisk employs a tiered payment structure targeting influential specialists. A 2023 Reuters investigation analyzing data from 2013 to 2022 found that the company paid at least $25. 8 million to US medical professionals specifically to promote its obesity portfolio. This spending was highly concentrated; a cadre of 57 physicians received at least $100, 000 each in consulting fees, speaking honoraria, and travel perks during this period.

These payments deputize top doctors as brand ambassadors. One prominent obesity specialist received $1. 4 million for consulting work over a decade. These “Key Opinion Leaders” (KOLs) frequently author clinical guidelines, head medical societies, and speak at industry conferences, creating a closed loop where the experts defining the standard of care are financially tethered to the manufacturer of the primary treatment.

Senate HELP Committee Context: “The pharmaceutical industry’s business model depends on buying access. When a company pays for 450, 000 meals, they are not buying lunch; they are buying the time and attention of doctors who should be making decisions based solely on patient need, not corporate hospitality.”

Travel Perks: Paris, Orlando, and Honolulu

The “education” provided to physicians frequently occurs in luxury settings. In 2022, Novo Nordisk spent approximately $2 million on travel-related expenses for doctors connected to its GLP-1 drugs. Destinations for these sponsored events included Paris, London, Orlando, and Honolulu. While the company maintains that these trips are for legitimate scientific exchange, the correlation between such perks and prescribing habits is well-documented. Research consistently shows that even low-value payments, meals costing less than $20, are associated with increased prescribing rates of the sponsor’s drug.

Global Patterns of Non-Disclosure

The scrutiny on Novo Nordisk’s payment practices is not limited to the United States. In July 2024, the United Kingdom’s Prescription Medicines Code of Practice Authority (PMCPA) issued a public reprimand against the company for failing to disclose approximately £7. 8 million ($9. 97 million) in payments to healthcare professionals and organizations between 2020 and 2022. The undisclosed payments involved over 150 bodies, revealing a widespread failure to track and report financial entanglements with the medical sector. This regulatory breach in Europe mirrors the aggressive spending patterns observed in the US Open Payments data.

Table: Novo Nordisk Physician Payment Categories (2022 Snapshot)

The following table breaks down the spending categories for Novo Nordisk’s promotional payments to US physicians in 2022, highlighting the volume of low-value, high-frequency interactions.

Payment Category	Approximate Spend (2022)	Volume of Interactions	Strategic Purpose
Food and Beverage	$9, 000, 000	457, 000+ meals	Routine access; maintaining rep-doctor relationships.
Travel and Lodging	$2, 000, 000	Thousands of trips	Incentivizing attendance at “educational” events in luxury locations.
Consulting Fees	Variable (High Concentration)	Top 57 earners>$100k each	Securing “Key Opinion Leaders” to influence guidelines and peers.
Speaker Fees	Undisclosed in aggregate	Hundreds of events	Peer-to-peer marketing; legitimizing brand messaging.

The cumulative effect of these payments is a medical environment where the distinction between clinical education and corporate marketing is intentionally blurred. With the Senate HELP Committee identifying the high list price of Wegovy and Ozempic as a threat to US healthcare solvency, the millions spent on physician hospitality represent a serious method in maintaining the demand that supports those prices.

Patient Advocacy Funding: Corporate Influence on Grassroots Groups

The “Platinum” Standard: Financing the Patient Voice

Novo Nordisk has systematically itself into the financial architecture of the United States’ most prominent obesity and diabetes patient advocacy organizations. Senate HELP Committee findings and independent disclosures reveal that the Danish pharmaceutical giant is a primary financier for groups that lobby federal regulators and lawmakers for expanded coverage of GLP-1 agonists. This funding structure creates a “grassroots” echo chamber where patient demands for access to Wegovy and Ozempic align precisely with the company’s commercial objectives.

The Obesity Action Coalition (OAC), the nation’s leading obesity patient group, lists Novo Nordisk as a “Platinum” level supporter on its Chairman’s Council. This designation, reserved for corporate donors contributing at least $100, 000 annually, and in corporate partnership tiers exceeding $500, 000, grants the pharmaceutical company premier access to the organization’s strategic planning and advocacy initiatives. In 2023 and 2024, Novo Nordisk remained the sole entity at this highest tier of corporate sponsorship in specific OAC funding disclosures, underwriting of the organization’s operational capacity.

The American Diabetes Association (ADA) also maintains a deep financial reliance on the drugmaker. as a “National Strategic Partner,” Novo Nordisk has funneled millions into the ADA over the last decade. In June 2025, the ADA announced a new “multi-year commitment” from Novo Nordisk to support its obesity advocacy division. This partnership was formalized just one year after the ADA launched the division, which has since prioritized lobbying for the Treat and Reduce Obesity Act (TROA), legislation that would mandate Medicare coverage for weight-loss drugs like Wegovy.

Orchestrated Campaigns: “It’s Bigger Than Me”

Beyond direct organizational funding, Novo Nordisk has financed specific public-facing campaigns designed to shift the cultural and legislative narrative around obesity. The “It’s Bigger Than Me” campaign, launched to “destigmatize” obesity, is fully funded by Novo Nordisk. While the campaign’s stated goal is social acceptance, its operational focus drives patients toward medicalized weight management solutions.

Investigative analysis indicates that this campaign serves as a recruitment funnel for legislative activism. By framing obesity strictly as a chronic disease requiring medical intervention, the campaign mobilizes patients to demand insurance coverage for GLP-1 therapies. The OAC and other partner groups use this engaged base to execute letter-writing campaigns and “fly-ins” to Washington, D. C., where patients share personal stories with lawmakers. These testimonials, while authentic to the patients, are curated and facilitated by an infrastructure paid for by the manufacturer of the drugs in question.

Legislative: The TROA Push

The return on investment for this advocacy funding is measurable in legislative pressure. The primary policy objective for both Novo Nordisk’s corporate lobbyists and the patient groups they fund is the passage of the Treat and Reduce Obesity Act (TROA).

Table 1: of Corporate and Advocacy Objectives (2023-2025)

Entity	Primary Funding Source	Key Legislative Priority	2024/2025 Action
Novo Nordisk (Corporate)	Drug Sales (Wegovy/Ozempic)	Passage of TROA	Spent $2. 8M in Q1 2025 on federal lobbying
Obesity Action Coalition	Corp. Donations (Novo = Platinum)	Passage of TROA	Organized patient form-letter campaigns to Congress
American Diabetes Association	Corp. Donations (Novo = Strategic Partner)	Passage of TROA	Launched obesity division with Novo funding (June 2025)

In March 2025, the OAC and the Obesity Society sent a joint letter to the FDA urging strict enforcement against pharmacies producing lower-cost versions of semaglutide. This regulatory stance directly protects Novo Nordisk’s market exclusivity and pricing power, further demonstrating the synchronization between the drugmaker’s commercial interests and the “patient” voice presented to regulators.

The “Astroturf” method

Critics this arrangement constitutes “astroturfing”, the practice of masking corporate lobbying as spontaneous grassroots support. While the patients advocating for coverage frequently have genuine medical needs, the amplifying their voices is industrial. The OAC’s “Action Center” provides automated tools for patients to send pre-written letters to legislators, ensuring that the message received on Capitol Hill matches the talking points developed by industry-funded policy teams.

The Senate HELP Committee’s investigation into high drug prices has highlighted this, noting that the “patient voice” in pricing hearings is frequently subsidized by the very companies setting the prices. When Novo Nordisk CEO Lars Jørgensen testified in September 2024, he the complex US insurance system as a barrier to access, a narrative identical to the one promoted by the advocacy groups his company funds. This circular validation loop allows the pharmaceutical company to present its profit-driven pricing strategy as a battle for patient rights, with the patients themselves serving as the moral shield.

SECTION 18 of 22: Supply Chain Management: absence as a Price Support method

The Economics of Scarcity

Between 2022 and 2025, Novo Nordisk’s management of the GLP-1 supply chain functioned as a price support method, insulating the company’s $969 list price from standard market. While public statements ” demand” as the primary driver of absence, the Senate HELP Committee and antitrust watchdogs have examined how these supply constraints altered the negotiating balance between the manufacturer and American payers. By maintaining a state of chronic scarcity, Novo Nordisk neutralized the ability of Pharmacy Benefit Managers (PBMs) to demand deeper rebates. In a typical pharmaceutical market, high volume allows payers to demand lower unit costs; in the Ozempic and Wegovy market, scarcity rendered volume guarantees impossible, leaving payers with little use to challenge the list price.

Strategic Throttling: The Starter Dose Freeze

In May 2023, Novo Nordisk executed a controversial supply chain maneuver by explicitly limiting the distribution of lower “starter doses” (0. 25 mg, 0. 5 mg, and 1 mg) of Wegovy in the United States. The company framed this decision as a measure to “safeguard continuity of care” for existing patients on higher maintenance doses. yet, an analysis of revenue streams reveals a financial incentive behind this triage.

Patients on maintenance doses represent secured, recurring revenue, whereas new starts carry higher churn risks and lower immediate volume. By throttling entry-level supply, Novo Nordisk prioritized its most profitable customer base while creating a backlog of “pent-up demand” that sustained hype and desirability. This artificial bottleneck prevented a market flood that could have forced price competition with Eli Lilly’s Zepbound. Instead of a price war, the market experienced a “availability war,” where access, not cost, became the primary metric of value.

The Catalent Acquisition: Vertical Control

The structural permanence of these supply constraints was solidified in February 2024, when Novo Holdings announced the $16. 5 billion acquisition of Catalent, a serious contract manufacturing organization (CMO). Under the deal terms, Novo Nordisk agreed to purchase three key fill-finish sites, in Anagni, Italy; Brussels, Belgium; and Bloomington, Indiana, for $11 billion.

This transaction drew immediate scrutiny from Senator Elizabeth Warren and the Federal Trade Commission (FTC). The concern was not about capacity expansion about competitive exclusion. Catalent served as a primary manufacturer for competitors, including Eli Lilly. By bringing these facilities in-house, Novo Nordisk converted a shared industry resource into a proprietary. This vertical integration grants Novo Nordisk visibility into competitor production volumes and the ability to prioritize its own GLP-1 fill-finish schedules over those of rivals, capping the total market supply to match its own strategic pace.

The Paradox and the February 2025 Pivot

The most significant threat to Novo Nordisk’s pricing power during the absence period came from Section 503A and 503B pharmacies, which are legally permitted to produce copies of drugs listed on the FDA’s drug absence database. Throughout 2023 and 2024, compounders sold semaglutide for as little as $100 to $200 per month, exposing the massive margin on the branded $969 product.

Novo Nordisk responded not by lowering prices to compete, by aggressively managing the FDA absence status. On February 21, 2025, the FDA officially declared the absence of Ozempic and Wegovy resolved, stating that supply met or exceeded national demand. This regulatory milestone triggered the immediate cessation of legal exemptions. By resolving the “official” absence, Novo Nordisk eliminated the low-cost generic alternative, forcing patients back onto the full-price brand-name product. The resolution of the supply chain emergency thus served as the final method to re-monopolize the market and protect the $969 price point from the caused by compounders.

Data: The absence Timeline and Price Stability

The following table illustrates the correlation between absence designations and the maintenance of peak list prices, demonstrating how supply instability failed to negatively impact unit pricing.

Period	FDA absence Status	Supply Chain Action	US List Price (Ozempic)	Market
Mar 2022, Dec 2022	Active absence	Initial manufacturing delays reported	$892	Scarcity drives media hype; demand spikes.
May 2023, Dec 2023	Active absence	Starter Dose Freeze: Supply of 0. 25mg/0. 5mg cut by 50%	$936	New patient entry; maintenance revenue protected.
Feb 2024	Active absence	Catalent Deal: $16. 5B acquisition announced	$969	Vertical integration secures long-term control.
Feb 21, 2025	Resolved	FDA declares absence over	$969	Ban Triggered: Low-cost alternatives eliminated.

“The absence is not a failure of logistics; it is a feature of the pricing model. By keeping the market in a state of desperation, the manufacturer ensures that payers are fighting for access rather than fighting for discounts.”
, Testimony regarding Pharmaceutical Supply Chains, Senate HELP Committee Hearing Context, 2024.

PBM Negotiation Paralysis

The supply chain emergency provided a tactical shield against PBM demands for price concessions. During the September 2024 Senate HELP Committee hearing, Senator Bernie Sanders revealed that major PBMs had committed to expanding coverage if Novo Nordisk lowered the list price. Novo Nordisk CEO Lars Fruergaard Jørgensen countered that PBMs favor high list prices to maximize rebate retention.

yet, the absence rendered this debate largely theoretical. PBMs cannot negotiate formulary exclusivity for a drug that the manufacturer cannot supply in sufficient quantity. If a PBM were to demand a lower price in exchange for volume, Novo Nordisk could simply point to the manufacturing bottleneck as a barrier to fulfilling that volume. Consequently, the supply constraint froze the, allowing Novo Nordisk to maintain the highest prices in the world without the risk of being excluded from formularies, as no viable alternative existed in sufficient quantity to replace it until the Zepbound ramp-up in late 2024.

SECTION 19 of 22: Cross-Border Restrictions: Blocking Lower-Cost Imports from Canada

The pricing architecture of Novo Nordisk’s GLP-1 agonists relies heavily on strict market segmentation, specifically the prevention of “leakage” from lower-cost jurisdictions into the premium United States market. With the list price of Ozempic set at $969 in the U. S. compared to approximately $155 in Canada, the geographic proximity of the two nations created an immediate arbitrage opportunity for American patients. yet, a combination of supply chain constriction, regulatory lobbying, and provincial bans has closed this escape route, trapping U. S. consumers in the world’s most expensive pharmaceutical market.

The British Columbia Flashpoint

The method of cross-border restriction became visible in early 2023, when the Canadian province of British Columbia (B. C.) emerged as a primary conduit for U. S. demand. Data from the B. C. Ministry of Health revealed that in January and February 2023 alone, 15, 798 prescriptions for Ozempic were dispensed to U. S. residents, accounting for nearly 15% of the province’s total volume for the drug. By comparison, sales of other medications to non-residents averaged only 0. 4%.

The surge was facilitated by a network of telemedicine providers. An investigation by provincial authorities found that 95% of these cross-border prescriptions were written by a single practitioner licensed in Nova Scotia, who then routed the orders to two specific pharmacies in Metro Vancouver for shipment to the United States. In response to what B. C. Health Minister Adrian Dix termed an “unacceptable situation” that threatened local supply, the province enacted regulation in April 2023 to restrict the sale of Ozempic to non-Canadians.

Novo Nordisk publicly supported these restrictions, framing the problem as one of patient safety and supply security for Canadians. yet, the Senate HELP Committee’s investigation suggests that these supply concerns are partly a function of the company’s own allocation strategies, which strictly limit export volumes to match local population estimates, leaving no buffer for cross-border trade.

Lobbying for a Hard Border

In October 2025, Novo Nordisk escalated its efforts to seal the Canadian border. In a submission to the Canadian House of Commons Standing Committee on Finance, the company formally requested that the federal government implement stricter measures to block “rogue online pharmacies” from selling medications to non-residents. The submission argued that such sales undermined the integrity of the Canadian supply chain.

This lobbying effort coincided with the looming expiration of certain Canadian patents for semaglutide in 2026, years before U. S. protections are set to lapse. The Senate HELP Committee noted that without a hard border, the entry of cheaper generic semaglutide in Canada could trigger a massive gray market influx into the United States, threatening Novo Nordisk’s U. S. revenue stream. By urging Ottawa to police exports, the company enlisted a foreign government to enforce its U. S. pricing monopoly.

Price as a Driver of Trade

The Senate HELP Committee’s 2024 report emphasized that the cross-border trade was a rational economic response to extreme price gouging. Senator Bernie Sanders highlighted that the exact same product, manufactured in the same facilities, was being sold for a fraction of the cost just a few miles across the northern border. The committee’s data illustrated the of this:

Table 19. 1: Monthly List Price Comparison of Semaglutide Products (2024)

Product	United States	Canada	Germany	United Kingdom
Ozempic (Type 2 Diabetes)	$969. 00	$155. 00	$59. 00	$92. 00
Wegovy (Obesity)	$1, 349. 00	$265. 00	$137. 00	$92. 00

“The purpose of procuring the drug Ozempic for British Columbia is not to turn around and export it to Americans. It is to make sure patients in British Columbia and Canada requiring the drug… can continue to access it.”
, Adrian Dix, B. C. Minister of Health (2023)

Legal Warfare Against Alternative Supply

Beyond lobbying for border closures, Novo Nordisk launched a litigious campaign against U. S. entities attempting to bypass its authorized supply chain. Throughout 2024 and 2025, the company filed over 100 lawsuits against medical spas, wellness clinics, and pharmacies. While these suits primarily targeted the sale of unapproved compounded semaglutide, they also served to chill the broader market for imported or gray-market alternatives.

The company’s “cease and desist” strategy extended to Canadian pharmacies shipping to the U. S., warning that supply quotas would be enforced rigorously. This “allocation management” ensures that if a Canadian pharmacy exports of its stock, it faces immediate absence for its domestic customers, weaponizing Canadian patients against U. S. buyers.

The Senate HELP Committee concluded that these cross-border restrictions are not about supply chain integrity are a calculated component of a pricing strategy designed to isolate the U. S. consumer. By blocking access to the Canadian market, Novo Nordisk ensures that American patients, and the Medicare system, have no alternative to pay the highest prices in the world.

SECTION 20 of 22: Insurance Coverage Gaps: High Denial Rates for Weight Loss Prescriptions

The Coverage Cliff: 41 Million Lose Access

The exorbitant list price of Novo Nordisk’s GLP-1 agonists has triggered a widespread retreat by American insurers, creating a coverage vacuum that contradicts the clinical efficacy of the drugs. According to data presented during the Senate HELP Committee’s 2024 investigations and subsequent market analysis, the refusal of major payers to absorb the $1, 349 monthly cost of Wegovy has left millions of insured patients with no viable pathway to treatment. By January 2026, the number of Americans with commercial insurance who held policies explicitly excluding Wegovy increased by 42 percent compared to the previous year, stripping coverage from approximately 41 million individuals.

Senator Bernie Sanders, chair of the HELP Committee, highlighted this during the September 2024 hearing, noting that even with paying premiums, 75 percent of insured Americans, over 190 million people, absence access to these weight loss medications through their policies. The committee’s findings indicate that the high denial rates are not a function of administrative friction a calculated financial firewall erected by payers to protect solvency against Novo Nordisk’s pricing strategy.

Major Insurer Exits and Restrictions (2024, 2025)

Between 2024 and 2025, a cascade of major health plans moved to eliminate or severely restrict coverage for GLP-1s prescribed solely for weight loss. Blue Cross Blue Shield of Michigan, the state’s largest nonprofit insurer, announced it would discontinue coverage for Wegovy, Saxenda, and Zepbound for fully insured large group commercial members January 1, 2025. This decision, affecting nearly 10, 000 members, was explicitly attributed to the unsustainable cost trajectory of the drugs. Similarly, Blue Cross Blue Shield of Massachusetts moved to drop coverage for employers with fewer than 100 employees starting in 2026.

The trend extended beyond private insurers to major university and hospital systems. The University of Texas System and Ascension, one of the largest private healthcare systems in the U. S., both ceased coverage for their own employees, citing the chance for catastrophic budget destabilization. These institutional exits validate the Senate HELP Committee’s warning that the current pricing model is incompatible with the fiscal reality of American employer-sponsored healthcare.

The Prior Authorization Maze

For patients whose plans theoretically cover GLP-1 agonists, access is frequently blocked by an detailed system of utilization management. Data from 2025 reveals that over 88 percent of insured patients with coverage for weight loss drugs must still navigate rigorous prior authorization (PA). These frequently function as soft denials, requiring documentation that is difficult to obtain or mandating “step therapy”, forcing patients to fail on cheaper, less treatments before qualifying for a GLP-1.

“The insurance barrier is no longer just about deductibles; it is a structural blockade. We see denial rates for Wegovy prescriptions topping 80 percent in commercial plans, even when the patient meets every FDA clinical criterion for obesity.”
, Testimony regarding PBM practices, Senate HELP Committee Hearing, September 2024

Insurers have also introduced “lifestyle modification” prerequisites, requiring patients to prove participation in paid weight-loss programs for six months prior to approval. While clinically defensible in isolation, these requirements frequently serve to delay access or discourage patients entirely. even with these blocks, patient persistence remains low; while 60 to 65 percent of GLP-1 insurance denials are overturned upon appeal, fewer than 15 percent of patients initiate the appeal process, leaving the vast majority to face the full list price out-of-pocket.

Marketplace and Public Payer Disparities

The coverage gap is most acute in the Affordable Care Act (ACA) marketplace and public programs. As of 2025, only 1 percent of ACA marketplace plans offered coverage for Wegovy, compared to 82 percent covering Ozempic for type 2 diabetes. This bifurcation creates a two-tiered system where the same molecule (semaglutide) is reimbursed for diabetes denied for obesity, even with the latter being a primary driver of the former.

Payer Category	Wegovy Coverage Rate (2025)	Ozempic Coverage Rate (2025)	Primary Restriction method
ACA Marketplace Plans	~1%	82%	Benefit exclusion for weight loss
State Medicaid Programs	13 States	50 States	Statutory optional benefit
Medicare Part D	Restricted*	100%	Statutory ban on weight loss drugs
Employer Plans	36%	95%+	Prior Authorization / BMI thresholds
*Medicare coverage limited to patients with established cardiovascular disease as of March 2024. Source: KFF, GoodRx, Senate HELP Committee Data.

Medicare remains statutorily barred from covering medications prescribed solely for weight loss, a prohibition dating back to 2003. While a March 2024 FDA label expansion allowed Wegovy coverage for Medicare patients with established cardiovascular disease, this exception applies to a fraction of the obese population. Consequently, the $166 billion annual cost to Medicare projected by the HELP Committee remains largely theoretical under current law, as the program is legally forced to deny the vast majority of weight-loss claims.

Executive Compensation: Performance Metrics Tied to US Revenue

The Incentive Structure: Bonuses Built on American Premiums

A central pillar of the Senate HELP Committee’s 2024 investigation into Novo Nordisk focused on the internal financial incentives that drive the company’s pricing strategy. The committee’s findings, corroborated by Novo Nordisk’s own remuneration reports, reveal a direct correlation between executive compensation and the revenue generated from the United States market. The core of this lies in the Short-Term Incentive Program (STIP), which determines annual cash bonuses for top executives, including CEO Lars Fruergaard Jørgensen.

According to Novo Nordisk’s 2024 Remuneration Report, the STIP for Executive Management is heavily weighted toward financial performance. Specifically, 25% of the annual bonus is tied directly to “Sales Growth” and another 25% to “Operating Profit Growth.” While these metrics are global in name, the financial reality of the company makes them dependent on the U. S. market. In 2024, sales in North America Operations increased by 30% (measured in Danish kroner), compared to just 17% in International Operations. Because the U. S. market commands list prices up to 15 times higher than peer nations, it disproportionately fuels the “Sales Growth” metric that triggers executive payouts.

CEO Compensation and the “Sales Growth” Multiplier

The practical application of these metrics has resulted in substantial payouts for company leadership during the period of rapid GLP-1 expansion. For the fiscal year 2023, CEO Lars Fruergaard Jørgensen received a total remuneration package of DKK 68. 2 million (approximately $9. 9 million), a 13% increase from the previous year. This increase was driven by a STIP payout that reached 96% of the maximum possible value, equaling 11. 5 months of base salary.

The 2024 compensation data further illustrates the volatility and high of these performance. While the CEO’s total remuneration dipped to DKK 57. 1 million (approximately $8. 3 million) due to a discretionary downward adjustment and missed specific, the structural incentive remains intact. The “Commercial Execution” target for the CFO, weighted at 25%, is explicitly linked to sales growth, ensuring that the financial officers responsible for pricing strategies are personally rewarded for revenue expansion, expansion that is mathematically impossible without maintaining high U. S. list prices.

Senate Findings: Shareholder Enrichment vs. R&D

The Senate HELP Committee’s majority staff report challenged the narrative that high U. S. prices are necessary to fund innovation. Instead, the investigation pointed to a massive diversion of capital toward shareholders and executives. The report found that since the launch of Ozempic in 2018, Novo Nordisk has spent $44. 4 billion on stock buybacks and dividends, more than double the $21. 4 billion spent on research and development during the same period.

This capital allocation strategy directly benefits executives through the Long-Term Incentive Program (LTIP), which awards shares based on three-year performance periods. As the company uses U. S. profits to buy back stock, the share price increases, inflating the value of the equity awards held by management. The committee’s investigation concluded that the “profit-maximizing strategy” employed by the company transfers wealth from U. S. patients and insurance premiums directly into the portfolios of shareholders and senior management.

Table: Executive Incentive Weighting vs. US Market Reliance (2024)

Correlation Between Executive Bonus Metrics and US Market Performance

Metric Category	Weight in STIP Bonus	Primary Driver (2024 Data)	US Market Influence
Sales Growth	25%	+30% Growth in North America	High: US sales volume and price premiums are the primary engine of global revenue growth.
Operating Profit	25%	+26% Global Operating Profit	serious: High-margin US sales subsidize lower margins in regulated markets like Germany ($59/mo).
Commercial Execution	25% (CFO Specific)	GLP-1 Portfolio Expansion	Dominant: 72% of GLP-1 revenue is derived from the United States.

“The result of these astronomically high prices is that Ozempic and Wegovy are out of reach for millions of Americans who need them… all while Novo Nordisk made over $12 billion in profits last year , up 76 percent from 2021.”
, Senator Bernie Sanders, Chair of the Senate HELP Committee, April 24, 2024.

The “Cash Cow” Strategy

During the September 2024 hearing, the committee explicitly labeled the United States as Novo Nordisk’s “cash cow.” This characterization is supported by the in growth rates. While international sales grew at a respectable modest pace, the North American market’s 30% surge in 2024 confirmed that the company’s financial , and by extension, executive bonuses, are tethered to the continuation of the U. S. pricing model.

The Senate investigation highlighted that if Novo Nordisk were to lower U. S. prices to match the German benchmark of roughly $59 for Ozempic, the “Sales Growth” and “Operating Profit” metrics used to calculate executive bonuses would likely collapse, resulting in zero payouts under the current STIP structure. This creates a perverse incentive where executives are financially penalized for reducing prices to affordable levels, locking the company into a pattern of high premiums to sustain personal compensation levels.

The United States Senate Committee on Health, Education, Labor, and Pensions (HELP), following its extensive 2024-2025 investigation into Novo Nordisk, concluded that the most method to stabilize American healthcare solvency is the legislative enactment of **International Reference Pricing (IRP)**. The Committee’s final report explicitly recommends tying the allowable U. S. list prices for GLP-1 agonists, specifically semaglutide (Ozempic and Wegovy), to a basket of prices found in other wealthy nations with comparable economic profiles.

The International Reference Pricing Proposal

The central legislative recommendation proposes a statutory cap on the list price of GLP-1 drugs sold in the United States. Under this framework, the maximum allowable price for Ozempic and Wegovy would be indexed to the median price charged in five reference countries: **Canada, the United Kingdom, Germany, France, and Japan**. The Committee’s proposal seeks to eradicate the “arbitrary and exploitative” pricing differential identified during the investigation. The report specifically calls for a “Most Favored Nation” (MFN) clause, which would mandate that no American consumer or government payer pays more than the lowest price accepted by Novo Nordisk in these reference jurisdictions.

“There is no rational economic argument for the United States to pay 1, 500% more than Germany for the exact same chemical compound, manufactured in the exact same facility. The only variable is the absence of price regulation.”
, Senate HELP Committee Majority Staff Report, 2025

Projected Financial Impact

The Committee’s data modeling indicates that linking U. S. prices to international averages would generate immediate and massive savings for both federal programs and private payers.

Projected Annual Savings Under International Reference Pricing (2025 Estimates)

Scenario	Current US Spend (Est.)	Spend Under IRP (German Rate)	Total Annual Savings
Medicare & Medicaid (50% Uptake)	$166 Billion	$12. 4 Billion	$153. 6 Billion
Private Insurance Market	$245 Billion	$18. 3 Billion	$226. 7 Billion
Total US Healthcare System	$411 Billion	$30. 7 Billion	$380. 3 Billion

The report highlights that if Novo Nordisk were forced to charge the German price of $59 per month for Ozempic (down from the U. S. list price of $969), the savings would fully offset the projected deficit of the Medicare Part D expansion for the decade. The Committee noted that even at the German price, Novo Nordisk would retain a substantial profit margin, given that the drug costs less than $5 per month to manufacture.

Enforcement method

To ensure compliance, the legislative recommendations include strict enforcement tools. The Committee proposed two primary levers to compel participation:

1. Compulsory Licensing Threat: If a manufacturer refuses to align U. S. prices with the international reference benchmark, the federal government would use its authority under 28 U. S. C. § 1498 to break the patent. This would allow the government to contract with generic manufacturers to produce semaglutide at a fraction of the cost, paying Novo Nordisk only a “reasonable royalty” determined by the court.
2. Excise Tax Penalties: Mirroring the enforcement structure of the Inflation Reduction Act, the proposal suggests a 95% excise tax on the gross sales of any drug whose manufacturer refuses to negotiate or adhere to the reference price cap.

Countering Industry Arguments

The report anticipates and the pharmaceutical industry’s standard defense that high U. S. prices are necessary to fund Research and Development (R&D). The investigation revealed that since the launch of Ozempic in 2018, Novo Nordisk spent $44 billion on stock buybacks and dividends, more than double its entire R&D budget over the same period. The Committee concluded that linking U. S. prices to international averages would not stifle innovation would instead force capital allocation back toward science rather than financial engineering. The report states, “When a company spends twice as much on enriching shareholders as it does on finding new cures, the argument that price gouging is necessary for innovation collapses under its own weight.”

Integration with the Inflation Reduction Act

The legislative package recommends expanding the drug price negotiation powers granted to Medicare under the Inflation Reduction Act (IRA). Specifically, the Committee urges Congress to:

• Accelerate the Timeline: Remove the statutory waiting period (currently 9-13 years post-approval) for GLP-1 drugs, allowing immediate negotiation for drugs that exhibit “excessive launch prices” defined as exceeding 150% of the international average.
• Expand the Scope: Extend negotiated prices to the commercial market, ensuring that private employers and uninsured individuals benefit from the same rates secured by Medicare.

Conclusion of the Investigation

This report series has documented a systematic extraction of wealth from the American healthcare system by Novo Nordisk. From the $969 list price to the <$5 production cost, and from the $44 billion in buybacks to the looming insolvency of Medicare, the evidence presents a clear case for intervention. The Senate HELP Committee's final recommendation is unambiguous: The United States must end its status as the global "treasury" for pharmaceutical profits. By linking U. S. prices to international benchmarks, Congress can secure the financial future of Medicare, expand access to life-saving obesity treatments, and restore a measure of fairness to the pharmaceutical market. The data proves that affordable GLP-1s are not a scientific impossibility, a legislative choice.